{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:06:20Z","timestamp":1769731580770,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"DOI":"10.7759\/cureus.19218","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T01:25:16Z","timestamp":1635902716000},"source":"Crossref","is-referenced-by-count":5,"title":["Belimumab in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"John","family":"Mwangi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase","family":"Litteken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya","family":"Gorthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeswanth","family":"Attoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40769","article-title":"Proceedings of the American College of Rheumatology\/Association of Physicians of Great Britain and Ireland connective tissue disease-associated interstitial lung disease summit: a multidisciplinary approach to address challenges and opportunities","volume":"71","author":"Fischer A","year":"2019","unstructured":"Fischer A, Strek ME, Cottin V, et al.. Proceedings of the American College of Rheumatology\/Association of Physicians of Great Britain and Ireland connective tissue disease-associated interstitial lung disease summit: a multidisciplinary approach to address challenges and opportunities. Arthritis Rheumatol. 2019, 71:182-95. 10.1002\/art.40769","journal-title":"Arthritis Rheumatol"},{"key":"ref2","article-title":"Glucocorticoids in systemic sclerosis: weighing the benefits and risks\u2014a systematic review","volume":"31","author":"Iudici M","year":"2013","unstructured":"Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks\u2014a systematic review. Clin Exp Rheumatol. 2013, 31:157-65.","journal-title":"Clin Exp Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin DP","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al.. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006, 354:2655-66. 10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-19. 10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer A","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM, et al.. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013, 40:640-6. 10.3899\/jrheum.121043","journal-title":"J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham JM","year":"2016","unstructured":"Oldham JM, Lee C, Valenzi E, et al.. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016, 121:117-22. 10.1016\/j.rmed.2016.11.007","journal-title":"Respir Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000487","article-title":"Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis","volume":"23","author":"Shimojima Y","year":"2017","unstructured":"Shimojima Y, Ishii W, Matsuda M, Kishida D, Ikeda SI. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol. 2017, 23:87-93. 10.1097\/RHU.0000000000000487","journal-title":"J Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014Subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells AU","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al.. Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014Subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir. Med. 2020, 8:453-60. 10.1016\/s2213-2600(20)30036-9","journal-title":"Lancet Respir. Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4236\/ojra.2012.23011","article-title":"Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia","volume":"2","author":"Matteson E","year":"2012","unstructured":"Matteson E, Bongartz T, Ryu JH, et al.. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis. 2012, 2:53-8. 10.4236\/ojra.2012.23011","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoimmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp C","year":"2016","unstructured":"Sharp C, McCabe M, Dodds N, et al.. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford). 2016, 55:1318-24. 10.1093\/rheumatology\/kew195","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir GJ","year":"2014","unstructured":"Keir GJ, Maher TM, Ming D, et al.. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014, 19:353-9. 10.1111\/resp.12214","journal-title":"Respirology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie R","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al.. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:3918-30. 10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.05.359","article-title":"Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus dspite immunosuppressive agents: a systematic review and meta-analysis","volume":"39","author":"Shamliyan TA","year":"2017","unstructured":"Shamliyan TA, Dospinescu P. Additional improvements in clinical response from adjuvant biologic response modifiers in adults with moderate to severe systemic lupus erythematosus dspite immunosuppressive agents: a systematic review and meta-analysis. Clin Ther. 2017, 39:1479-1506.e45. 10.1016\/j.clinthera.2017.05.359","journal-title":"Clin Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316682097","article-title":"Belimumab for the treatment of recalcitrant cutaneous lupus","volume":"26","author":"Vashisht P","year":"2017","unstructured":"Vashisht P, Borghoff K, O'Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017, 26:857-64. 10.1177\/0961203316682097","journal-title":"Lupus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/67890-belimumab-in-the-treatment-of-connective-tissue-disease-associated-interstitial-lung-disease-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:04Z","timestamp":1707507364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/67890-belimumab-in-the-treatment-of-connective-tissue-disease-associated-interstitial-lung-disease-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.19218","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,2]]}}}